TY - JOUR
T1 - Measuring health-related quality of life in sarcopenia
T2 - summary of the SarQoL psychometric properties
AU - Beaudart, Charlotte
AU - Reginster, Jean Yves
AU - Amuthavalli Thiyagarajan, Jotheeswaran
AU - Bautmans, Ivan
AU - Bauer, Jürgen
AU - Burlet, Nansa
AU - Cesari, Matteo
AU - Cherubini, Antonio
AU - Cooper, Cyrus
AU - Cruz-Jentoft, Alfonso J.
AU - Dawson-Hughes, Bess
AU - Fielding, Roger A.
AU - Harvey, Nicholas C.
AU - Landi, Francesco
AU - Laslop, Andrea
AU - Maggi, Stefania
AU - Montero-Errasquin, Beatriz
AU - Concepción, Prieto Yerro María
AU - Rolland, Yves
AU - Rizzoli, René
AU - Visser, Marjolein
AU - Bruyère, Olivier
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/8
Y1 - 2023/8
N2 - Patient perspectives are now widely recognized as a key element in the evaluation of health interventions. Therefore, the provision of specific and validated Patient Reported Outcome Measures that emphasize the lived experience of patients suffering from specific diseases is very important. In the field of sarcopenia, the only validated specific health-related quality of life (HRQoL) instrument available is the Sarcopenia Quality of Life questionnaire (SarQoL). This self-administrated HRQoL questionnaire, developed in 2015, consists of 55 items arranged into 22 questions and has currently been translated into 35 languages. Nineteen validation studies performed on SarQoL have consensually confirmed the capacity of SarQoL to detect difference in HRQoL between older people with and without sarcopenia, its reliability and its validity. Two further observational studies have also indicated its responsiveness to change. A short form SarQoL, including only 14 items has further been developed and validated to reduce the potential burden of administration. Research on the psychometric properties of SarQoL questionnaire is still encouraged as the responsiveness to change of SarQoL has not yet been measured in the context of interventional studies, as limited prospective data currently exist and as there is still not cut-off score to define a low HRQoL. In addition, SarQoL has mainly been used in community-dwelling older individuals with sarcopenia and would benefit to be studied in other types of populations. This review aims to provide to researchers, clinicians, regulators, pharmaceutical industries and other stakeholders a clear summary of comprehensive evidence on the SarQoL questionnaire published up to January 2023Query.
AB - Patient perspectives are now widely recognized as a key element in the evaluation of health interventions. Therefore, the provision of specific and validated Patient Reported Outcome Measures that emphasize the lived experience of patients suffering from specific diseases is very important. In the field of sarcopenia, the only validated specific health-related quality of life (HRQoL) instrument available is the Sarcopenia Quality of Life questionnaire (SarQoL). This self-administrated HRQoL questionnaire, developed in 2015, consists of 55 items arranged into 22 questions and has currently been translated into 35 languages. Nineteen validation studies performed on SarQoL have consensually confirmed the capacity of SarQoL to detect difference in HRQoL between older people with and without sarcopenia, its reliability and its validity. Two further observational studies have also indicated its responsiveness to change. A short form SarQoL, including only 14 items has further been developed and validated to reduce the potential burden of administration. Research on the psychometric properties of SarQoL questionnaire is still encouraged as the responsiveness to change of SarQoL has not yet been measured in the context of interventional studies, as limited prospective data currently exist and as there is still not cut-off score to define a low HRQoL. In addition, SarQoL has mainly been used in community-dwelling older individuals with sarcopenia and would benefit to be studied in other types of populations. This review aims to provide to researchers, clinicians, regulators, pharmaceutical industries and other stakeholders a clear summary of comprehensive evidence on the SarQoL questionnaire published up to January 2023Query.
KW - HRQoL
KW - Psychometric properties
KW - Quality of life
KW - Sarcopenia
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=85160260815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160260815&partnerID=8YFLogxK
U2 - 10.1007/s40520-023-02438-3
DO - 10.1007/s40520-023-02438-3
M3 - Review article
C2 - 37219755
AN - SCOPUS:85160260815
SN - 1594-0667
VL - 35
SP - 1581
EP - 1593
JO - Aging Clinical and Experimental Research
JF - Aging Clinical and Experimental Research
IS - 8
ER -